^
4d
Uncovering the predictive and immunomodulatory potential of transient receptor potential melastatin family-related CCNE1 in pan-cancer. (PubMed, Mol Cancer)
These findings indicate that the TRPM family-particularly CCNE1, which is associated with TRPM-is a significant player in the pan-cancer domain and can be utilized as a therapeutic target and prognostic biomarkers, especially in immuno-oncology. The thorough characterization of the TRPM family and the discovery of CCNE1 as a crucial downstream effector mark important developments in our comprehension of pan-cancer biology.
Journal • PD(L)-1 Biomarker • IO biomarker • Pan tumor • Immunomodulating
|
PD-L1 (Programmed death ligand 1) • CCNE1 (Cyclin E1)
|
PD-L1 expression • CCNE1 expression
2ms
Rho GTPase activating protein 11A promotes tongue squamous cell carcinoma proliferation and is a transcriptional target of forkhead box M1. (PubMed, J Dent Sci)
This study revealed the oncogenic role of ARHGAP11A in TSCC, highlighting its impact on cell-cycle control and tumor proliferation. Furthermore, the regulatory relationship between FOXM1 and ARHGAP11A provides new insights into the transcriptional networks in TSCC.
Journal
|
CCNE1 (Cyclin E1) • RHOA (Ras homolog family member A) • FOXM1 (Forkhead Box M1)
|
CCNE1 expression • RHOA mutation • CDKN1B expression
7ms
AURKB promotes colorectal cancer progression by triggering the phosphorylation of histone H3 at serine 10 to activate CCNE1 expression. (PubMed, Aging (Albany NY))
Furthermore, it was showed that the inhibitor specific for AURKB (AZD1152) can suppress CCNE1 expression in CRC cells and inhibit tumor cell growth. To conclude, this research demonstrates that AURKB accelerated the tumorigenesis of CRC through its potential to epigenetically activate CCNE1 expression, suggesting AURKB as a promising therapeutic target in CRC.
Journal • Epigenetic controller
|
CCNE1 (Cyclin E1) • AURKB (Aurora Kinase B)
|
CCNE1 expression
|
barasertib (AZD1152)
7ms
Differential cyclin-E1 expression in CIC-rearranged sarcoma. (PubMed, Ann Diagn Pathol)
However, the correlation between cyclin E1 expression level and survival was not statistically significant. This is the first study that shows cyclin E1 immunohistochemical expression in EWSR1-negative undifferentiated small cell sarcomas, particularly CRS.
Journal
|
CCNE1 (Cyclin E1) • EWSR1 (EWS RNA Binding Protein 1) • CD99 (CD99 Molecule) • DUX4 (Double Homeobox 4)
|
CCNE1 expression
7ms
Apoptotic Effect of Isoimpertorin via Inhibition of c-Myc and SIRT1 Signaling Axis. (PubMed, Int J Mol Sci)
Furthermore, Isoimperatorin suppressed the overexpression of c-Myc by the proteasome inhibitor MG132 and also disturbed cycloheximide-treated c-Myc stability in Huh7 cells. Overall, these findings support the novel evidence that the pivotal role of c-Myc and SIRT1 is critically involved in Isoimperatorin-induced apoptosis in HCCs as potent molecular targets in liver cancer therapy.
Journal • PARP Biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • SIRT1 (Sirtuin 1)
|
MYC overexpression • MYC expression • CCND1 expression • CCNE1 expression • CDK2 expression • CDK6 expression
|
MG132
7ms
The Clinicopathological Significance of the Cyclin D1/E1-Cyclin-Dependent Kinase (CDK2/4/6)-Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers. (PubMed, Int J Mol Sci)
Our data not only identified the prognostic/predictive significance of these key cell cycle regulators but also demonstrate the importance of sub-cellular localisation. CDK2 targeting in cyclin-E1-amplified OCs could be a rational approach.
Journal
|
RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • CDK2 (Cyclin-dependent kinase 2)
|
CCNE1 amplification • CCNE1 overexpression • CCND1 expression • CCND1 expression + CDK4 expression • CCNE1 expression
8ms
CircROR1 upregulates CCNE1 expression to promote melanoma invasion and metastasis by recruiting KAT2A. (PubMed, Exp Dermatol)
CircROR1 upregulates CCNE1 expression through KAT2A-mediated histone acetylation. Our research confirms the critical role of CircROR1 in melanoma invasion and metastasis, and CircROR1 could serve as a potential therapeutic target for melanoma treatment.
Journal
|
CCNE1 (Cyclin E1) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • MMP9 (Matrix metallopeptidase 9)
|
CCNE1 overexpression • CCNE1 expression
8ms
Oleanolic acid promotes liver regeneration after partial hepatectomy via regulating pregnane X receptor signaling pathway in mice. (PubMed, Chem Biol Interact)
Silencing of Pxr further confirmed that OA-mediated upregulation of proliferation-related proteins depended on PXR. The current study illustrated that OA exhibited a significant promoting effect on liver regeneration following PHx, potentially through regulation of the PXR signaling pathway to accelerate liver recovery.
Preclinical • Journal
|
CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • FOXO1 (Forkhead box O1) • PCNA (Proliferating cell nuclear antigen) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • RBL2 (RB Transcriptional Corepressor Like 2)
|
CCND1 expression • UGT1A1*1*1 • CCNE1 expression • CDKN1B expression • PCNA expression
8ms
"Keep on ROCKIn": Repurposed ROCK inhibitors to boost corneal endothelial regeneration. (PubMed, Biomed Pharmacother)
In compared parameters, Chroman-1 at a concentration of 10 nM outperformed other ROCKi, requiring significantly 1000-fold lower effective concentration than established ROCKi Y-27632 and Fasudil. Altogether, this study underscores the potential of repurposing ROCKi for treating corneal endothelial dysfunctions, offering a viable alternative to conventional grafting methods, and highlights Chroman-1 as a promising candidate structure for hit-to-lead development.
Journal
|
CCNE1 (Cyclin E1) • CDK2 (Cyclin-dependent kinase 2) • TJP1 (Tight Junction Protein 1)
|
CCNE1 expression • CDK2 expression
9ms
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays. (PubMed, NPJ Breast Cancer)
Similarly, the CDK4/6 inhibitor abemaciclib appears to inhibit proliferation better than palbociclib because it also restricts cellular overgrowth through off-target effects. Together, this demonstrates why CDK4/6 inhibitors, and any other anti-cancer drugs that arrest the cell cycle but permit continued cell growth, must now be re-screened against a wide-range of cell types using an appropriate proliferation assay. This would help to better inform clinical trials and to identify much needed biomarkers of response.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • CDK2 (Cyclin-dependent kinase 2) • SKP2 (S-phase kinase-associated protein 2)
|
HER-2 negative • CCND1 expression • CCNE1 expression
|
Ibrance (palbociclib) • Verzenio (abemaciclib)
11ms
cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer. (PubMed, NPJ Breast Cancer)
Moreover, data from the I-SPY2 clinical trial (n = 71) confirms that higher cGAS-STING scores are observed in breast cancer patients who responded to immunotherapy combined with chemotherapy. In conclusion, the cGAS-STING pathway is highly expressed in TNBCs and is correlated with genomic instability and immune cell infiltration.
Journal • Tumor mutational burden • IO biomarker • Immune cell
|
TMB (Tumor Mutational Burden) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • HRD (Homologous Recombination Deficiency) • CD20 (Membrane Spanning 4-Domains A1) • CCNE1 (Cyclin E1) • CD4 (CD4 Molecule) • CGAS (Cyclic GMP-AMP Synthase) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
|
HRD • MYC expression • CCNE1 expression
11ms
Anti-breast cancer activity of biosynthesized selenium nanoparticles using Bacillus coagulans supernatant. (PubMed, J Trace Elem Med Biol)
The obtained results indicated that SeNPs had strong potential to induce significant cell apoptosis and are cytotoxic against the MCF-7 cancer cell line.
Journal • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • CCND1 expression • BAX expression • CCNE1 expression
12ms
Polo-like kinase 1 inhibitor NMS-P937 represses nasopharyngeal carcinoma progression via induction of mitotic abnormalities. (PubMed, J Biochem Mol Toxicol)
ROS scavenger N-acetylcysteine partially reversed ROS levels induced by NMS-P937. Overall, NMS-P937 suppressed NPC cell proliferation and increased ROS levels, causing cell cycle abnormalities and apoptosis. NMS-P937 holds great promise as a therapeutic agent for treating nasopharyngeal carcinoma.
Journal • PARP Biomarker
|
CCNE1 (Cyclin E1) • PLK1 (Polo Like Kinase 1) • CASP3 (Caspase 3) • CCNB1 (Cyclin B1)
|
CCNE1 expression
|
onvansertib (PCM-075)
12ms
CX3CR1-Expressing Immune Cells Infiltrate the Tumor Microenvironment and Promote Radiation Resistance in a Mouse Model of Lung Cancer. (PubMed, Cancers (Basel))
CX3CR1-expressing mononuclear cells invade the TME after radiation therapy in a mouse lung cancer model. CX3CR1 cell depletion attenuates tumor progression following radiation and sensitizes the tumor to S-phase-specific chemotherapy. Thus, we propose a novel strategy to improve radiation sensitivity by targeting the CX3CR1-expressing immune cells.
Preclinical • Journal • Immune cell
|
CCNE1 (Cyclin E1) • IL6 (Interleukin 6) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
|
CCNE1 expression
|
gemcitabine
1year
Real-world clinical genomics study of HR+/HER2- metastatic breast cancers treated by CDK4/6i plus endocrine therapies revealed a drug resistant tumor segment characterized by ER independence (SABCS 2023)
Conclusions Our real-world clinical genomics study identified a comprehensive list of biomarkers associated with resistance to CDK4/6i plus ET and estimated patient prevalence for these markers in the post-treatment setting. Integrated and machine-learning analyses identified a subset of aggressive tumors with estrogen independence characteristics that are implicated in CDK4/6i resistance and suggested new therapeutic strategies.
Real-world evidence • Clinical • Genomic study • BRCA Biomarker • Real-world • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • CDK4 (Cyclin-dependent kinase 4) • CDK2 (Cyclin-dependent kinase 2)
|
TP53 mutation • HR positive • HER-2 negative • RB1 mutation • MYC expression • PGR expression • CCNE1 expression
|
Tempus xT Assay
1year
Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib + endocrine therapy in HR+/HER2- metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trial (SABCS 2023)
PAM50 intrinsic subtype was significantly associated with PFS with second-line palbociclib + ET. Lower expression of BCAS was associated with improved OS outcomes with palbociclib + ET independent of intrinsic subtype, and for the Immune1 TCGA BRCA GES, lower expression corresponded with improved OS with palbociclib + ET compared to capecitabine. This informs recent findings that in HR+/HER2- breast cancer, tumor immune activity may be a negative predictor of CDK4/6i benefit.
Clinical • BRCA Biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CCNE1 (Cyclin E1) • BRCA (Breast cancer early onset)
|
HER-2 negative • CCNE1 expression
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Ibrance (palbociclib) • capecitabine
1year
MCTS1 enhances the proliferation of laryngeal squamous cell carcinoma via promoting OTUD6B-1 mediated LIN28B deubiquitination. (PubMed, Biochem Biophys Res Commun)
OTUD6B or LIN28B shRNA weakened MCTS1 overexpression-induced cyclin D1 and c-Myc protein expression and LSCC cell proliferation. In summary, this study revealed that MCTS1 could enhance LSCC proliferation partially via the OTUD6B-LIN28B axis.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • OTUD6B (OTU Deubiquitinase 6B) • LIN28B (Lin-28 Homolog B)
|
MYC expression • CCND1 overexpression • CCNE1 expression • MCT1 overexpression
1year
Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer. (PubMed, J Pathol)
BQ overexpression reverses the effect of anastrozole in ER+ve breast cancer in an AR-dependent manner, whilst co-treatment with the AR antagonist bicalutamide recovered its therapeutic effect both in vitro and in vivo.
Journal
|
ER (Estrogen receptor) • CCNE1 (Cyclin E1) • CDK4 (Cyclin-dependent kinase 4) • NCOR2 (Nuclear Receptor Corepressor 2) • CDK2 (Cyclin-dependent kinase 2)
|
ER positive • CCNE1 overexpression • AR expression • CCNE1 expression • CDK2 expression
|
anastrozole • bicalutamide
1year
PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors. (PubMed, Cell Biochem Biophys)
In CCNE1 amplificated colorectal tumor cells, knockdown of PKMYT1 reduced cells in S phase, inhibited cell proliferation and promoted cell apoptosis, confirming that PKMYT1 was a potential therapeutic target for colorectal tumor. This study may verify a potential therapeutic target and provide a new idea for the treatment of colorectal cancer in the future.
Journal
|
CCNE1 (Cyclin E1) • CDK1 (Cyclin-dependent kinase 1) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1)
|
CCNE1 amplification • CCNE1 overexpression • CCNE1 expression
1year
Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice. (PubMed, Cell Death Dis)
In summary, we provide evidence that Ccne1 expression in a small population of HSCs is sufficient to trigger extensive liver fibrosis and hepatocarcinogenesis in a Cdk2-dependent manner. Thus, HSC-specific targeting of Ccne1 or Cdk2 in patients with liver fibrosis and high risk for HCC development could be therapeutically beneficial.
Preclinical • Journal
|
CCNE1 (Cyclin E1) • CDK2 (Cyclin-dependent kinase 2)
|
CCNE1 expression
over1year
A Positive Feedback Loop of lncRNA HOXD-AS2 and SMYD3 Facilitates Hepatocellular Carcinoma Progression via the MEK/ERK Pathway. (PubMed, J Hepatocell Carcinoma)
Additionally, HOXD-AS2 was uncovered to be positively regulated at transcriptional level by its downstream gene of SMYD3. HOXD-AS2, a novel oncogenic HOX-lncRNA, facilitates HCC progression by forming a positive feedback loop with SMYD3 and activating the MEK/ERK pathway.
Journal
|
CCNE1 (Cyclin E1) • MMP2 (Matrix metallopeptidase 2) • SMYD3 (SET And MYND Domain Containing 3) • CCNB1 (Cyclin B1)
|
CCNE1 expression
over1year
Patchouli alcohol induces G /G cell cycle arrest and apoptosis in vincristine-resistant non-small cell lung cancer through ROS-mediated DNA damage. (PubMed, Thorac Cancer)
PA induced ROS-mediated DNA damage, triggered cell cycle arrest and apoptosis, attenuated drug resistance and cancer stem cell phenotypes, and synergistically inhibited proliferation in combination with cisplatin. These findings suggest that PA has the potential to be used for the treatment of NSCLC with or without VCR resistance.
Journal
|
CCNE1 (Cyclin E1) • CHEK1 (Checkpoint kinase 1) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
CCNE1 expression
|
cisplatin • vincristine
over1year
Long noncoding RNA LINC02568 sequesters microRNA-874-3p to facilitate malignancy in breast cancer cells via cyclin E1 overexpression. (PubMed, Oncol Res)
In conclusion, the tumor-promoting functions of LINC02568 in breast cancer cells were enhanced by sequestering miR-874-3p and consequently over-expressing CCNE1. Our data may facilitate the identification of novel therapeutic targets in clinical settings.
Journal
|
CCNE1 (Cyclin E1)
|
CCNE1 overexpression • CCNE1 expression
over1year
Aloin inhibits gastric cancer cell proliferation and migration by suppressing the STAT3/HMGB1 signaling pathway (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
Aloin attenuates the proliferation and migration of gastric cancer cells by inhibiting the STAT3/HMGB1 signaling pathway.
Journal
|
CCNE1 (Cyclin E1) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • HMGB1 (High Mobility Group Box 1) • MMP9 (Matrix metallopeptidase 9) • CCNB1 (Cyclin B1)
|
CDH1 expression • CCNE1 expression
over1year
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. (PubMed, Clin Cancer Res)
We provide rationale for combining T-DXd with adavosertib in HER2-expressing cancers, especially with co-occuring CCNE1 amplifications.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CCNE1 (Cyclin E1)
|
HER-2 overexpression • HER-2 amplification • HER-2 expression • CCNE1 amplification • CCNE1 overexpression • CCNE1 expression
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • adavosertib (AZD1775)
over1year
Copy number variations and protein expression of Cyclin E1 and Epithelial cell transforming sequence 2 genes predict the chemotherapeutic response in patients with serous ovarian carcinoma. (PubMed, Pak J Med Sci)
Statistically significant difference was found between the mean pre-chemotherapy protein levels of CCNE1 in cases than controls (p-value <0.001) and between the mean pre and post-chemotherapy protein levels of CCNE1 and ECT2 (p-value <0.001) in SOC patients. The copy number variations of CCNE1 and ECT2 genes and their protein expression are positively associated with chemotherapeutic response in SOC patients.
Journal
|
CCNE1 (Cyclin E1) • MUC16 (Mucin 16, Cell Surface Associated)
|
CCNE1 expression
over1year
Circular RNA circSEMA5A facilitates colorectal cancer development by regulating microRNA-195-5p to target CCNE1 axis. (PubMed, Cell Signal)
To summarize, circSEMA5A is a novel circRNA that serves as an oncogene in CRC progression. CircSEMA5A facilitates CRC cell malignancy and tumor growth through sponging miR-195-5p to upregulate CCNE1, thus providing a new direction for CRC diagnosis and targeted therapy.
Journal
|
CCNE1 (Cyclin E1) • SEMA5A (semaphorin 5A) • MIR195 (MicroRNA 195)
|
CCNE1 overexpression • CCNE1 expression
over1year
Lycopene suppresses gastric cancer cell growth without affecting normal gastric epithelial cells. (PubMed, J Nutr Biochem)
Lycopene decreased the high expression levels of CCNE1 and increased the levels of TP53 in AGS and SGC-7901 cells without affecting those in GES-1 cells. In summary, lycopene could effectively suppress gastric cancer cells with CCNE1-amplification, which could be a promising target therapy reagent for gastric cancer.
Journal
|
CCNE1 (Cyclin E1)
|
TP53 mutation • CCNE1 amplification • CCNE1 expression
over1year
Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study. (ASCO 2023)
Abemaciclib not reported due to low numbers (n=16). We confirmed independent prognostic value of CES in first-line setting, suggesting a not statistically significant benefit with ribociclib vs palbociclib in CES-I. >
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • FOXA1 (Forkhead Box A1) • MIA (MIA SH3 Domain Containing) • MLPH (Melanophilin)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • CCND1 expression • CCNE1 expression
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)
over1year
Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC). (ASCO 2023)
This open-label, multicenter study (NCT04516447) assessed azenosertib + paclitaxel (PAC), carboplatin (Carbo), gemcitabine (GEM), or pegylated liposomal doxorubicin (PLD) in pts with metastatic high-grade serous EOC after ≤2 lines of CT including platinum CT. Azenosertib + CT is well tolerated and has encouraging clinical activity, with durable responses in pts with platinum R/R EOC. Pts with Cyclin E1 overexpressing tumors, a subgroup with suboptimal benefits from CT, demonstrated significant improvements in ORR and PFS vs pts with tumors having low expression. These data support a planned trial of azenosertib + CT vs CT alone in Cyclin E1 overexpressing platinum R/R EOC.
Clinical • Clinical data • P1 data • Combination therapy
|
CCNE1 (Cyclin E1)
|
CCNE1 amplification • CCNE1 overexpression • CCNE1 expression
|
carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • azenosertib (ZN-c3)
over1year
Primary efficacy analyses of NeoRHEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer. (ASCO 2023)
High pre-treatment mRNA expression of the CDK6 gene was associated with no US response or absence of CCCA in patients treated with neoadjuvant palbociclib and ET. Independent validation is needed. Clinical trial information: NCT03065621.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • IFNG (Interferon, gamma)
|
HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • CCNE1 expression • CDK6 expression
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Ibrance (palbociclib)
over1year
CCNE1 and PLK1 mediates resistance to palbociclib in HR+/HER2- metastatic breast cancer. (PubMed, Clin Cancer Res)
We confirm the association of non-luminal subtype and CCNE1 with resistance to CDK4/6i+ET in HR+ MBC. High levels of PLK1 mRNA identify patients with poor response to palbociclib, suggesting PLK1 could also play a role in the setting of resistance to CDK4/6i.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CCNE1 (Cyclin E1) • PLK1 (Polo Like Kinase 1)
|
ER positive • HR positive • HER-2 negative • CCNE1 overexpression • CCNE1 expression
|
Ibrance (palbociclib) • capecitabine
over1year
Unexpected function of the cell cycle kinase Cyclin E/CDK2 for control of intestinal barrier: implications for gut-liver communication, liver fibrosis and liver cancer (EASL-ILC 2023)
Cyclin E1 is an important driver of liver fibrosis and HCC. These functions are mediated at least in part through HSC activation. We provide unexpected evidence that the Cyclin E/CDK2 complex is involved in the control of intestinal permeability.
IO biomarker
|
CCNE1 (Cyclin E1) • CDK2 (Cyclin-dependent kinase 2) • CCNE2 (Cyclin E2) • TJP1 (Tight Junction Protein 1)
|
CCNE1 expression
over1year
CCNE1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis. (PubMed, Hereditas)
Our study demonstrated that CCNE1 is upregulated in multiple cancers in the TCGA database and may be a promising predictive biomarker for the immunotherapy response in some types of cancers. Moreover, CCNE1 knockdown can suppress the proliferation, migration and invasion of UCEC cells.
Journal • Tumor mutational burden • IO biomarker • Pan tumor
|
CCNE1 (Cyclin E1)
|
CCNE1 expression
over1year
Accelerated Discovery of Macrocyclic CDK2 Inhibitor QR-6401 by Generative Models and Structure-Based Drug Design. (PubMed, ACS Med Chem Lett)
Selective CDK2 inhibitors have the potential to provide effective therapeutics for CDK2-dependent cancers and for combating drug resistance due to high cyclin E1 (CCNE1) expression intrinsically or CCNE1 amplification induced by treatment of CDK4/6 inhibitors...Here we report the discovery of a highly potent and selective macrocyclic CDK2 inhibitor QR-6401 (23) accelerated by the application of generative models and structure-based drug design (SBDD). QR-6401 (23) demonstrated robust antitumor efficacy in an OVCAR3 ovarian cancer xenograft model via oral administration.
Journal
|
CCNE1 (Cyclin E1)
|
CCNE1 amplification • CCNE1 expression
|
Undisclosed CDK4/6 inhibitor
over1year
Short or long-term treatment with CDK4/6 inhibitors in patients with ER+ breast cancer: characterization and comparative analysis of resistance in seventeen XPDX models (AACR 2023)
We have established, characterized, and compared a panel of seventeen breast XPDX models from fourteen female patients representing early or late acquired resistance to CDK4/6i therapy and identified potential differences in each set. These models and resulting data are useful in developing novel therapies for CDK4/6i-resistant patients.
Clinical
|
ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)
|
PIK3CA mutation • ER mutation • RB1 deletion • ESR1 mutation • CCND1 expression • CCNE1 expression • CDK6 expression
over1year
Tumor heterogeneity of CCNE1 copy number assessed by fluorescence in situ hybridization (FISH) in ovarian and uterine cancers and correlation with cyclin E protein expression (AACR 2023)
Substantial intratumoral spatial heterogeneity of CCNE1 copy number when measured by FISH was observed across ovarian and uterine tumors. The potential impact of CCNE1 amplification heterogeneity, cyclin E1 protein levels and CCNE1 amplification fragment size on response to RP-6306 in preclinical models are currently being investigated and will be reported.
CCNE1 (Cyclin E1) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1)
|
CCNE1 amplification • CCNE1 expression
|
lunresertib (RP-6306)
over1year
Troponin T1 Promotes the Proliferation of Ovarian Cancer by Regulating Cell Cycle and Apoptosis. (PubMed, Iran J Biotechnol)
In conclusion, TNNT1 overexpression promotes SKOV3 cell growth and tumorigenesis by inhibiting cell apoptosis and accelerating cell-cycle progression. TNNT1 might be a potent biomarker for the treatment of ovarian cancer.
Journal
|
CCND1 (Cyclin D1) • CCNE1 (Cyclin E1)
|
CCND1 expression • CCNE1 expression
almost2years
Molecular landscape and clinical implication of CCNE1-amplified esophagogastric cancer. (ASCO-GI 2023)
"While there were no differences in OS between CCNE1-amp vs non-amp GA, CCNE1Amp was associated with worse OS after trastuzumab in the IHC HER2+ cohort (N=9 vs 28; HR (95% CI): 2.95 (1.18 – 7.34), p = 0.015)...CCNE1Amp is associated with a distinct molecular profile in EGC and resistance to HER2-targeted therapy. While CCNE1-amp tumors are thought to be generally “immune-cold,”CCNE1-amp GA demonstrated potentially improved outcomes with immunotherapy. Further investigation of CCNE1Amp as a predictive biomarker is warranted, particularly as novel therapeutics selectively targeting CCNE1Amp are under clinical investigation."
Clinical
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCNE1 (Cyclin E1) • CDH1 (Cadherin 1)
|
PD-L1 expression • HER-2 positive • MSI-H/dMMR • HER-2 amplification • HER-2 mutation • CCNE1 amplification • CDKN2A mutation • HER-2 amplification + PD-L1 expression • CCNE1 expression • PD-L1 expression + MSI-H/dMMR
|
PD-L1 IHC 22C3 pharmDx
|
Herceptin (trastuzumab)